Ototoxicity and drugs of ingredients of alendronate sodium - a phase IV clinical study of FDA data
Ototoxicity is reported only by a few people who take drugs with ingredients of alendronate sodium. This phase IV clinical study analyzes 146,083 people who have side effects while taking drugs with ingredients of alendronate sodium from the the FDA. Among them, 4 have Ototoxicity. Find out below who they are, when they have Ototoxicity and more.
Drug(s) considered in the study (i.e. both brand name and generic drugs): Alendronate sodium, Alendronic acid, Binosto, Fosamax.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
146,083 people reported to have side effects when taking drugs with ingredients of alendronate sodium.
Among them, 4 people (0.0%) have Ototoxicity
What is Ototoxicity?
Ototoxicity (damage to the ear) is found to be associated with 595 drugs and 333 conditions by eHealthMe.
Number of reports submitted per year:
Gender of people who have Ototoxicity when taking drugs with ingredients of alendronate sodium *:
- female: 75 %
- male: 25 %
Age of people who have Ototoxicity when taking drugs with ingredients of alendronate sodium *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 50 %
- 50-59: 0.0 %
- 60+: 50 %
Conditions people have *:
- Pneumonia: 1 person, 25.00%
Other drugs people take *:
- Folic Acid: 2 people, 50.00%
- Omeprazole: 2 people, 50.00%
- Zoloft: 1 person, 25.00%
- Lansoprazole: 1 person, 25.00%
- Albuterol Sulfate: 1 person, 25.00%
- Azathioprine: 1 person, 25.00%
- Azithromycin: 1 person, 25.00%
- Enoxaparin Sodium: 1 person, 25.00%
- Gabapentin: 1 person, 25.00%
- Ganciclovir: 1 person, 25.00%
Other side effects people have besides Ototoxicity *:
- Tinnitus (a ringing in the ears): 2 people, 50.00%
- Vision Blurred: 1 person, 25.00%
- Neuropathy Peripheral (surface nerve damage): 1 person, 25.00%
- Hyperacusis (disorder in loudness perception): 1 person, 25.00%
- Earache (ear pain): 1 person, 25.00%
- Dizziness: 1 person, 25.00%
- Deafness Transitory (deafness temporary): 1 person, 25.00%
* Approximation only. Some reports may have incomplete information.
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
- Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
Drugs with ingredients of alendronate sodium, their effectiveness, alternatives and more:
How the study uses the data?
The study uses data from the FDA. It is based on alendronate sodium. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.